Relay Medical and Swiss PharmaCan AG Appoint Former Nestle Brand Manager and Leafly Marketing Director as Chief Commercial Officer of Glow LifeTech

Toronto, Ontario–(Newsfile Corp. – April 27, 2020) – Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay” or the “Company“), a developer of MedTech innovation, and Swiss PharmaCan AG, an award-winning European bio-tech company, are pleased to announce the appointment of Marketing Executive Rob Carducci as Chief Commercial Officer (CCO) of Glow LifeTech Ltd. Mr. Carducci’s appointment takes effect immediately.

Robert Carducci is a seasoned marketing executive with over a decade of leadership experience building iconic global brands including Delissio, Drumstick, Smarties and KitKat. Most recently Rob served as Marketing Director for the largest cannabis information website in the world Leafly.com, owned by Leafly Holdings, Inc.

“We are very excited to welcome Rob to the team as CCO of Glow. Given the opportunity and diversity of Glow’s product lines and potential it is imperative to have someone adept in navigating the world of international CPG and brand management. Rob’s experience as a leader driving brands and marketing initiatives for household names and the largest cannabis tech platform in the world makes him a one of a kind asset to the Company at this stage in its commercial development.” said Yoav Raiter, CEO, Relay Medical Corp.

“Over the course of my career, I’ve had the privilege of leading brand and business building for some of the world’s biggest food brands and in the fast-paced cannabis technology start-up world. Glow is at the forefront of the future of food and nutraceuticals, with a technology and product portfolio that has the power to meaningfully improve the health of millions of people. I look forward to bringing my capabilities to Glow to help more people experience the power of plants.” said Rob Carducci, CCO, Glow LifeTech Ltd.

As CCO, Rob will be responsible for building the commercialization strategy and infrastructure to drive market adoption for Glow’s technology and product portfolio across North America. Rob will provide strategic leadership for defining the commercial path to growth and profitability, and lead the development of the company’s marketing, sales & business development strategy.

Initial Product Line

Glow most recently announced the company’s initial product line including Curcumin, Cannabis products and Immune Boost C-O-C that includes Curcumin, Olibanum and Vitamin-C.

The technology allows Glow to formulate cannabinoids and nutraceuticals with dramatically improved absorption, fast-acting onset, precise dosing and superior health benefits, using all-natural ingredients, to meet the growing demands for next generation value-add products. Under the executed agreement Glow LifeTech has acquired the exclusive rights to the technology and the initial production of Curcumin, Cannabis, Iron, and Vitamin K in North America.

About Swiss Pharmacan AG and Micelle Technology AG

Micelle Technology AG, parent company of Swiss Pharmacan is a dynamic organization dedicated to R&D using natural active ingredients (i.e. vitamins and minerals) to improve human health. As one of the leading innovators of plant-based micelle concentrates, Micelle Technology AG offers a unique technology, which enables the company to harness the full potential of herbal active ingredients.

Swiss Pharmacan recently announced the signing of an agreement with MGC Pharmaceuticals Ltd. for necessary research support, commercial manufacturing and distribution of a natural anti-infective based formulation with the aim to treat serious viral infections with inflammatory complications. The Product is based on the Parties’ patented MyCell Enhanced™ delivery system technology.

About Relay Medical Corp.

Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and data science sectors.

Website: www.relaymedical.com

Contact Information:

Relay Medical Corp.

W. Clark Kent
President
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
Email: investor.relations@relaymedical.com

Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: blanger@relaymedical.com

Swiss Pharmacan AG and Micelle Technology AG
Mellingerstrasse 10
5443 Niederrohrdorf
Switzerland
Tel: +41 56 508 78 10
Email: info@swisspharmacan.ch

Glow LifeTech Ltd.
James Van Staveren
Corporate Development & Research
Glow LifeTech Ltd.
Tel: 647-244-7229
Email: jamesv@glowlifetech.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for HemoPalm Corp./UXD Data Sciences Corp. and/or Glow LifeTech Ltd. described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/54958